Position in AKBA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$54,351
-$8,588 QoQ
Shares Held
39,102
+0.0% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Arax Advisory Partners holds $1,714,453 across 41 Drug Manufacturers - Specialty & Generic names. AKBA ranks #8 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
681 | $403,819 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
10,694 | $322,103 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
1,432 | $188,651 | |
| 4 | ZTS |
Zoetis Inc.
|
1,527 | $180,506 | |
| 5 | VTRS |
Viatris Inc
|
10,932 | $147,691 | |
| 6 | TAK |
Takeda Pharmaceutical Co Ltd
|
4,343 | $80,432 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
2,408 | $57,623 | |
| 8 | AKBA |
Akebia Therapeutics, Inc.
This page
|
39,102 | $54,351 |
All Filings in AKBA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $54,351 | 39,102 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $62,939 | 39,093 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $108,108 | 39,600 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $90,333 | 24,817 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $47,648 | 24,817 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $26,030 | 13,700 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||